CLOs on the Move

Broadlane

www.broadlane.com

 
The Broadlane Group is a leading end-to-end cost management partner for healthcare providers, with product offerings grouped into six service lines that allow healthcare providers to maximize cost efficiencies and invest in the delivery of quality patient care.
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Tufts Health Care Institute

Tufts Health Care Institute is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

LAB Research Inc

LAB Research Inc is a Laval, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

JW Nutritional

JW Nutritional strives to maintain a high quality of business from communication all the way to product fulfillment to ensure the success of our clients.

Jewish Hospital and St. Mary's HealthCare, Inc.

Jewish Hospital & St. Mary's HealthCare, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Louisville, KY. To find more information about Jewish Hospital & St. Mary's HealthCare, Inc., please visit www.jhsmh.org

Sernova

Sernova Corp. is a clinical-stage biotechnology company that is developing its Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells, for the treatment of chronic diseases such as insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. On implantation, the Cell Pouch forms a natural vascularized tissue environment in the body for the long-term survival and function of therapeutic cells that release essential factors absent or deficient in patients with certain chronic diseases. Sernova is also advancing a proprietary technology to shield therapeutic cells from immune system attacks with the goal to eliminate the need for chronic, systemic immunosuppression. In May 2022, the Company announced a global strategic partnership with Evotec, providing Sernova with a potentially unlimited supply of insulin-producing islet cells to treat patients with insulin-dependent diabetes (type 1 and type 2). Sernova continues to progress additional development programs utilizing its Cell Pouch System: a cell therapy for hypothyroid disease resulting from thyroid gland removal and an ex-vivo lentiviral Factor VIII gene therapy for hemophilia A.